S
Steven Gallinger
Researcher at Ontario Institute for Cancer Research
Publications - 587
Citations - 55353
Steven Gallinger is an academic researcher from Ontario Institute for Cancer Research. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 99, co-authored 502 publications receiving 48181 citations. Previous affiliations of Steven Gallinger include Mount Sinai Hospital, Toronto & Cancer Care Ontario.
Papers
More filters
Journal ArticleDOI
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
TL;DR: The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem Cells.
Journal ArticleDOI
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore,David Goldstein,John T. Hamm,Arie Figer,J. R. Hecht,Steven Gallinger,Heather J. Au,Pawel Murawa,David Walde,Robert A. Wolff,D. M. B. Campos,Robert Lim,Keyue Ding,Gary M. Clark,Theodora Voskoglou-Nomikos,Mieke Ptasynski,Wendy R. Parulekar +16 more
TL;DR: To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
Journal ArticleDOI
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Christine Ribic,Daniel J. Sargent,Malcolm J. Moore,Malcolm J. Moore,Stephen N. Thibodeau,Amy J. French,Richard M. Goldberg,Stanley R. Hamilton,Stanley R. Hamilton,Pierre Laurent-Puig,Robert Gryfe,Lois E. Shepherd,Dongsheng Tu,Mark Redston,Steven Gallinger,Steven Gallinger +15 more
TL;DR: F fluorouracil-based adjuvant chemotherapy benefited patients with stage II or stage III colon cancer with microsatellite-stable tumors or tumors exhibiting low-frequency micros satellite instability but not those with tumors exhibiting high-frequencymicrosatellite instability.
Journal ArticleDOI
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin,Andrew V. Biankin,Andrew V. Biankin,Nicola Waddell,Karin S. Kassahn,Marie-Claude Gingras,Lakshmi Muthuswamy,Amber L. Johns,David Miller,Peter Wilson,Ann-Marie Patch,Jianmin Wu,David K. Chang,David K. Chang,David K. Chang,Mark J. Cowley,Brooke Gardiner,Sarah Song,Ivon Harliwong,Senel Idrisoglu,Craig Nourse,Ehsan Nourbakhsh,Suzanne Manning,Shivangi Wani,Milena Gongora,Marina Pajic,Christopher J. Scarlett,Christopher J. Scarlett,Anthony J. Gill,Anthony J. Gill,Anthony J. Gill,Andreia V. Pinho,Ilse Rooman,Matthew J. Anderson,Oliver Holmes,Conrad Leonard,Darrin Taylor,Scott Wood,Qinying Xu,Katia Nones,J. Lynn Fink,Angelika N. Christ,Timothy J. C. Bruxner,Nicole Cloonan,Gabriel Kolle,Felicity Newell,Mark Pinese,R. Scott Mead,R. Scott Mead,Jeremy L. Humphris,Warren Kaplan,Marc D. Jones,Emily K. Colvin,Adnan Nagrial,Emily S. Humphrey,Angela Chou,Angela Chou,Venessa T. Chin,Lorraine A. Chantrill,Amanda Mawson,Jaswinder S. Samra,James G. Kench,James G. Kench,James G. Kench,Jessica A. Lovell,Roger J. Daly,Neil D. Merrett,Neil D. Merrett,Christopher W. Toon,Krishna Epari,Nam Q. Nguyen,Andrew Barbour,Nikolajs Zeps,Nipun Kakkar,Fengmei Zhao,Yuan Qing Wu,Min Wang,Donna M. Muzny,William E. Fisher,F. Charles Brunicardi,Sally E. Hodges,Jeffrey G. Reid,Jennifer Drummond,Kyle Chang,Yi Han,Lora Lewis,Huyen Dinh,Christian J. Buhay,Timothy Beck,Lee Timms,Michelle Sam,Kimberly Begley,Andrew M.K. Brown,Deepa Pai,Ami Panchal,Nicholas Buchner,Richard de Borja,Robert E. Denroche,Christina K. Yung,Stefano Serra,Nicole Onetto,Debabrata Mukhopadhyay,Ming-Sound Tsao,Patricia Shaw,Gloria M. Petersen,Steven Gallinger,Steven Gallinger,Ralph H. Hruban,Anirban Maitra,Christine A. Iacobuzio-Donahue,Richard D. Schulick,Christopher L. Wolfgang,Richard A. Morgan,Rita T. Lawlor,Paola Capelli,Vincenzo Corbo,Maria Scardoni,Giampaolo Tortora,Margaret A. Tempero,Karen M. Mann,Nancy A. Jenkins,Pedro A. Perez-Mancera,David J. Adams,David A. Largaespada,Lodewyk F. A. Wessels,Alistair G. Rust,Lincoln Stein,David A. Tuveson,Neal G. Copeland,Elizabeth A. Musgrove,Elizabeth A. Musgrove,Aldo Scarpa,James R. Eshleman,Thomas J. Hudson,Robert L. Sutherland,Robert L. Sutherland,David A. Wheeler,John V. Pearson,John Douglas Mcpherson,Richard A. Gibbs,Sean M. Grimmond +140 more
TL;DR: It is found that frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, are also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement ofAxon guidance genes in pancreatic carcinogenesis.
Journal ArticleDOI
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent,Silvia Marsoni,Geneviève Monges,Stephen N. Thibodeau,Roberto Labianca,Stanley R. Hamilton,Amy J. French,Brian Kabat,Nathan R. Foster,Valter Torri,Christine Ribic,Axel Grothey,Malcolm J. Moore,Alberto Zaniboni,Jean Francois Seitz,Frank A. Sinicrope,Steven Gallinger +16 more
TL;DR: Data support MMR status assessment for patients being considered for FU therapy alone and consideration of MMR status in treatment decision making and patient stratification by MMR status may provide a more tailored approach to colon cancer adjuvant therapy.